FDA staff question value of Sanofi blood clot drug

Hot Searches

FDA staff question value of Sanofi blood clot drug

WASHINGTON (Reuters) - U.S. drug reviewers questioned the value of preventing blood clots with Sanofi SA's semuloparin injection for cancer patients receiving chemotherapy.... Full Article @ Reuters - 1 year ago

14 Research + 6 Full Reads

Track this article across the web

Trending Upwards

3M Adds New Products to Cavilon Brand Portfolio

BusinessWire
MdBio Foundation Names New Board Members

BusinessWire
Dezima Pharma Appoints Seasoned New CEO

BusinessWire
Patterson Companies Declares Quarterly Dividend

BusinessWire
Siemens Sponsors Landmark PBS Cancer Documentary

BusinessWire
Phyton Biotech recebe CEP por API docetaxel

BusinessWire
Research and Markets: Celgene Partnering 2005-2013

BusinessWire
Introducing Goody’s® Headache Relief Shot™

BusinessWire
HCA to Present at June Healthcare Conferences

BusinessWire
Javelina Now Powering EBS-RMSCO

BusinessWire
AVEO Oncology Announces Strategic Restructuring

BusinessWire
ARIAD to Present at Upcoming Investor Conferences

BusinessWire
Commonwealth Care Open Enrollment Underway

BusinessWire
ICIG Announces New CordenPharma Management Team

BusinessWire
Why using e-book makes your memory dull

IBNLive

Related Videos

Hot Searches

FDA staff question value of Sanofi blood clot drug

Similar Articles

Track this article across the web

Trending Upwards